5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.56▼ | 1.56▼ | 1.56▼ | 1.59▼ | 1.70▼ |
MA10 | 1.56▼ | 1.56▼ | 1.56▼ | 1.64▼ | 1.68▼ |
MA20 | 1.56▼ | 1.56▼ | 1.56▼ | 1.71▼ | 1.77▼ |
MA50 | 1.56▼ | 1.58▼ | 1.61▼ | 1.74▼ | 2.21▼ |
MA100 | 1.58▼ | 1.62▼ | 1.69▼ | 1.85▼ | 1.90▼ |
MA200 | 1.61▼ | 1.71▼ | 1.69▼ | 2.21▼ | 3.41▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▲ | 0.002▲ | 0.004▲ | -0.017▼ | -0.002▼ |
RSI | 46.302▼ | 46.162▼ | 45.324▼ | 42.507▼ | 42.727▼ |
STOCH | 65.278 | 32.606 | 60.819 | 26.662 | 43.414 |
WILL %R | -75.000▼ | -88.889▼ | -42.105 | -82.701▼ | -78.519▼ |
CCI | -69.136 | -46.667 | 17.812 | -99.173 | -113.706▼ |
CDL | $IKT Harami Candlestick Pattern Detected | Set Alert |
Tuesday, August 19, 2025 06:00 AM
BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify ...
|
Thursday, August 14, 2025 03:53 PM
Inhibikase Therapeutics pursues new therapies for serious diseases like Parkinson's Disease and pulmonary arterial hypertension (PAH). The current business focus is advancing lead product candidates ...
|
Thursday, August 14, 2025 03:53 PM
with costs heavily impacted by recent acquisition charges. Research and development and selling, general, and administrative expenses surged year over year. R&D expenses increased compared to the same ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/09/25 | 1.58 | 1.60 | 1.55 | 1.56 | 57,447 |
15/09/25 | 1.54 | 1.60 | 1.4962 | 1.60 | 157,294 |
12/09/25 | 1.68 | 1.68 | 1.55 | 1.56 | 78,651 |
11/09/25 | 1.56 | 1.73 | 1.50 | 1.68 | 98,291 |
10/09/25 | 1.64 | 1.6425 | 1.525 | 1.54 | 107,764 |
09/09/25 | 1.66 | 1.68 | 1.6049 | 1.67 | 33,254 |
08/09/25 | 1.68 | 1.73 | 1.65 | 1.66 | 48,552 |
05/09/25 | 1.70 | 1.70 | 1.66 | 1.67 | 209,450 |
04/09/25 | 1.73 | 1.73 | 1.655 | 1.71 | 75,322 |
03/09/25 | 1.75 | 1.80 | 1.71 | 1.73 | 113,579 |
|
|
||||
|
|
||||
|
|